Table 3 Stratified analysis of pooled HRs for cancer patients in different subgroups
Variable | No. of studies | No. of Patients | HR (95% CI) | Heterogeneity | Model | ||
|---|---|---|---|---|---|---|---|
χ2 | I2 | P Value | |||||
Cyp24A1 detection | |||||||
  protein | 4 | 761 | 1.14 (1.02, 1.26) | 4.69 | 36.00% | 0.196 | random |
  mRNA | 4 | 1479 | 1.24 (1.01, 1.46) | 4.84 | 38.10% | 0.184 | random |
  methylation | 2 | 125 | 2.18(1.41, 2.96) | 0.13 | 0.00% | 0.717 | random |
  SNP | 5 | 1419 | 1.42 (1.16, 1.68) | 3.51 | 0.00% | 0.476 | random |
Cancer type | |||||||
  lung cancer | 7 | 1244 | 1.15 (1.05, 1.26) | 9.03 | 33.60% | 0.172 | random |
  Colorectal cancer | 3 | 448 | 2.48 (1.13, 3.83) | 0.11 | 0.00% | 0.948 | random |
  breast cancer | 2 | 1471 | 1.82 (1.16, 2.47) | 0.168 | 0.00% | 0.614 | random |
Treatment | |||||||
  non-treatment | 10 | 2149 | 1.18 (1.07, 1.28) | 16.95 | 46.90% | 0.049 | random |
  treatment | 5 | 1635 | 1.42 (1.17, 1.68) | 3.22 | 0.00% | 0.521 | random |
Sample size | |||||||
   > 100 | 9 | 3369 | 1.34(1.17, 1.50) | 11.4 | 0.299 | 0.18 | random |
   < 100 | 6 | 415 | 1.15(1.03, 1.27) | 8.59 | 0.418 | 0.127 | random |
ethnicity | |||||||
  unknown | 8 | 1798 | 1.51(1.27, 1.75) | 6.53 | 0.00% | 0.48 | random |
  China | 3 | 481 | 1.11(1.01, 1.23) | 3.57 | 44.00% | 0.168 | random |
  North America | 2 | 1284 | 1.35(1.09, 1.60) | 1.81 | 44.70% | 0.179 | random |